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Abstract. Human serum amyloid P (hSAP), a member of the 
pentraxin family, inhibits the activation of fibrocytes in culture 
and inhibits experimental renal, lung, skin and cardiac fibrosis. 
As hepatic inflammation is one of the causes of liver fibrosis, in 
the present study, we investigated the hepatoprotective effects of 
hSAP against carbon tetrachloride (CCl4)-induced liver injury. 
Our data indicated that hSAP attenuated hepatic histopatholog-
ical abnormalities and significantly decreased inflammatory cell 
infiltration and pro-inflammatory factor expression. Moreover, 
CCl4-induced apoptosis in the mouse liver was inhibited by 
hSAP, as measured by terminal-deoxynucleotidyl transferase 
mediated nick-end labeling (TUNEL) assay and cleaved 
caspase-3 expression. hSAP significantly restored the expression 
of B cell lymphoma/leukemia (Bcl)-2 and suppressed the expres-
sion of Bcl-2-associated X protein (Bax) in vivo. The number 
of hepatocytes in early apoptosis stained with Annexin V was 
significantly reduced by 28-30% in the hSAP treatment group 
compared with the CCl4 group, and the expression of Bcl-2 was 
increased, whereas the expression of Bax and cleaved caspase-3 
were significantly inhibited in the hSAP pre-treatment group 
compared with the CCl4 group. hSAP administration also inhib-
ited the migration and activation of hepatic stellate cells (HSCs) 
in CCl4-injured liver and suppressed the activation of isolated 
primary HSCs induced by transforming growth factor (TGF)-β1 
in vitro. Collectively, these findings suggest that hSAP exerts 
a protective effect againts CCl4-induced hepatic injury by 
suppressing the inflammatory response and hepatocyte apop-
tosis, potentially by inhibiting HSC activation.
Introduction
Liver injury is generally considered to be a result of exposure 
to high levels of environmental toxins and is associated with 
metabolic dysfunctions ranging from the transient elevation of 
liver enzymes to life-threatening hepatic fibrosis, liver cirrhosis 
and even hepatocellular carcinoma (1). Liver inflammation is 
commonly associated with hepatocyte necrosis and apoptosis (2). 
Apoptotic hepatocyte bodies can activate quiescent hepatic 
stellate cells (HSCs) and Kupffer cells, and these activated cell 
populations in turn promote inflammation and fibrogenesis (2). 
Activated HSCs also increase the production of inflammatory 
chemokines (3), the expression of adhesion molecules (4) and 
the presentation of antigens to T lymphocytes and natural killer 
T cells (5). These enhanced inflammation and immune responses 
can promote hepatocyte necrosis and apoptosis, and thereby 
strengthen and perpetuate the stimuli for fibrogenesis (6). The 
sustained suppression of inflammatory activity by eliminating 
the etiological agent (7-9) or by dampening the immune 
response (10,11) can halt and even reverse fibrotic progression. 
The success of current treatments for chronic liver inflammation 
in achieving anti-fibrotic effects can be measured by prolonged 
survival and possibly by the reduced occurrence of hepatocel-
lular carcinoma (7,12,13).Therefore, hepatic inflammation is one 
of the causes of fibrosis, cirrhosis and hepatocellular carcinoma.
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Serum amyloid P (SAP), a member of the pentraxin family 
of proteins, has been shown to inhibit fibrosis in a number 
of organ sites in preclinical animal models, in part due to 
the inhibition of the differentiation of circulating collagen I+ 
cells (14,15). These cells have been demonstrated to be involved 
in the pathology associated with bleomycin-induced lung 
fibrosis (16). In previously published articles conducted using 
the bleomycin model of lung fibrosis in mice and rats (15), 
intra-peritoneal injections of purified rat SAP (rSAP) into rats, 
or purified mouse SAP (mSAP) into mice, significantly reduced 
fibrocyte and macrophage recruitment to the lungs, as well as 
myofibroblast activation and collagen deposition. SAP injec-
tions also reduced bleomycin-induced leukocyte infiltration 
into rat lungs (15) and transforming growth factor (TGF)-β1-
induced lung inflammation in mice (17). As liver fibrosis shares 
similar biological signals with fibrosis in a number of different 
organ models, and as hepatic fibrosis commonly follows 
chronic inflammation (6), we hypothesized that human serum 
amyloid P (hSAP) may exert protective effects on hepatocytes 
during hepatic inflammation/fibrosis.
Promedior, Inc. (Malvern, PA, USA) recently developed 
PRM-151, a recombinant form of hSAP. Cross-species compar-
ison assays in vitro demonstrated comparable efficacy of human 
serum-derived SAP (hSAP), recombinant hSAP (rhSAP) and 
mSAP or rSAP for inhibiting mouse or rat monocytes from fibro-
cyte differentiation. Additionally, cross-species comparison 
assays in vitro demonstrated comparable efficacy for hSAP and 
rhSAP at inhibiting human and cynomolgus monkey fibrocyte 
differentiation (18). Taken together, these results confirmed 
the conservation of biological function across species. In this 
study, we investigated the protective effects of hSAP against 
carbon tetrachloride (CCl4)-induced acute liver injury in mice, 
including hepatoprotective and anti-inflammatory effects in 
acute liver injury, as well as the potential of hSAP to inhibit the 
migration and activation of HSCs.
Materials and methods
hSAP. hSAP is formulated in a P5SP vehicle (10 mM sodium 
phosphate, 5% (w/v) sorbitol and 0.01% (w/v) polysorbate 20, 
pH 7.5) at a concentration of 1.25 mg/ml. The drug was shipped 
frozen and was stored at -20˚C until initial use. The frozen drug 
was gently thawed, and vigorous agitation was avoided.
Animal use and care. Male C57BL/6 8-week-old mice, 
weighing 20.0±2 g, were purchased from Vital River 
Laboratories (Beijing, China). The mice were maintained 
in a pathogen-free environment in the animal facilities at 
Beijing Friendship Hospital. All protocols were approved 
by the Beijing Friendship Hospital Animal Care and Ethics 
Committee (13-2006).
The mice were randomly allocated into 7 groups (n=8 in 
each group). Group I (normal) was administered the same 
volume of solvent (olive oil) by intraperitoneal injection. In the 
second and third groups (CCl4-exposed groups, 24 and 48 h), 
acute liver injury was induced by the administration of a single 
intraperitoneal dose of CCl4 (10 µl/g) dissolved in olive oil (1:7). 
In the fourth and fifth groups (hSAP-treated + CCl4-exposed 
groups, 24 and 48 h), the mice first received an intravenous 
dose of hSAP (12.5 mg/kg); they were then intraperitone-
ally injected with a single dose of CCl4 2 h later, in the same 
manner as the CCl4-exposed group. In the sixth and seventh 
groups (vehicle-treated + CCl4-exposed group, 24 and 48 h), the 
mice received the same procedure, but received the vehicle at 
the same volume as hSAP. At 24 h (24 h group) and 48 h (48 h 
group) after the CCl4 injection, the mice were sacrificed under 
anesthesia. Some liver tissues were fixed in 4% paraformalde-
hyde for subsequent histological examination and some liver 
tissues were stored at -80˚C for further experiments.
Histological examination and terminal-deoxynucleotidyl 
transferase mediated nick-end labeling (TUNEL) assay. Liver 
samples were fixed in 4% paraformaldehyde, paraffin embedded 
and sectioned. Hematoxylin and eosin (H&E) staining was 
performed by Wuhan Goodbio Technology Co., Ltd. (Wuhan, 
China). Necrotic hepatocytes show distinctive cytoplasmic 
eosinophilia, abnormal sizes and contours and nuclear pyknosis 
and karyorrhexis. Five high-power fields at x200 magnification 
were randomly selected, and the degree of cellular death due to 
necrosis was analyzed semiquantitatively using image analysis 
with the National Institutes of Health image program (ImageJ) 
following the user's guide (http://imagej.net/docs/guide). 
Immunohistochemistry was performed on paraffin-embedded 
mouse liver sections using the specific antibody for 
CD45 (GB11066; Wuhan Goodbio Technology Co., Ltd.), 
desmin (D93F5; Cell Signaling Technology, Danvers, MA, 
USA) and α-smooth muscle actin (α-SMA; ab5694; Abcam, 
Cambridge, MA, USA) to detect inflammatory cells and HSCs 
in livers. The negative control was the replacement of primary 
antibody with non-immune serum. For the detection of cell 
apoptosis, TUNEL assay was performed following the manu-
facturer's instructions (11684795910; Roche, Indianapolis, 
IN, USA). In each tissue specimen, 5 high-power fields at 
x200 magnification were randomly selected, and the percentage 
of positive cells was quantified using ImageJ software.
Primary HSC isolation and cell culture. Primary HSCs were 
isolated from 3 wild-type C57BL/6 8-week-old mice by a 
2-step collagenase-pronase perfusion of mouse livers followed 
by 8.2% Nycodenz (Accurate Chemical and Scientific Corp., 
Westbury, NY, USA). Two-layer discontinuous density gradient 
centrifugation was performed as previously described (19). 
Isolated HSCs were cultured in Dulbecco's modified Eagle's 
medium (DMEM; Gibco, Grand Island, NY, USA) containing 
10% fetal bovine serum. For HSC activation experiments 
in vitro, the cells were cultured overnight in serum-free 
medium prior to the experiments. The HSCs were then cultured 
with hSAP (30 µg/ml) or vehicle for 4 h before stimulation 
with TGF-β1 (10 ng/ml for 24 h; PeproTech, Rocky Hill, 
NJ, USA) (20). Following 24 h of incubation, all cells were 
harvested for further experiments.
Dual-fluorescent immunohistochemistry and Oil Red O 
staining for the identification of isolated primary HSCs. 
Isolated primary HSCs seeded on sterile slides were fixed with 
4% paraformaldehyde and permeated with 0.1% Triton X-100. 
Non-specific binding was blocked with 1% bovine serum 
albumin for 30 min. The cells were then incubated with 
primary antibodies against desmin (D93F5; Cell Signaling 
Technology) at 4˚C overnight, followed by secondary 
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antibodies for 40 min. Nuclei were counterstained with 
4',6-diamidino-2-phenylindole (DAPI) (Invitrogen, Carlsbad, 
CA, USA) for 5 min. To detect lipid droplets in freshly isolated 
HSCs, the cells were fixed in ice-cold 4% paraformaldehyde 
for 20 min at room temperature prior to incubation for 10 min 
in a saturated solution of Oil Red O (G1016; Wuhan Goodbio 
Technology Co., Ltd.) in isopropanol. The slides were coun-
terstained with Mayer's haematoxylin. Images were captured 
using a fluorescence microscope (Nikon, Tokyo, Japan).
Hepatocyte cell line and apoptosis assay. To avoid the adverse 
effects of hepatocyte injury produced during perfusion on the 
detection of cell death, we used the mouse hepatocyte cell 
line, NCTC 1469 (Cell Resource Center, Chinese Academy of 
Medical Sciences and Peking Union Medical College) to detect the 
potential protective effects of hSAP on hepatocyte death induced 
by CCl4. NCTC 1469 cells were cultured with hSAP (30 µg/ml) 
or the vehicle for 4 h prior to stimulation with CCl4 (2.5 mM 
for 4 h), as previously described (21). We used DMSO to 
dissolve CCl4 and DMSO is the vehicle control. Apoptosis was 
assessed using a PE Annexin V apoptosis detection kit (559763; 
BD Pharmingen, San Jose, CA, USA) following the manufac-
turer's instructions. The cells were analyzed with a FACSCalibur 
flow cytometer (Becton-Dickinson, San Jose, CA, USA), and the 
cells considered viable were PE-negative and 7-AAD-negative. 
Cells in early apoptosis were PE Annexin V-positive and 
7-AAD-negative, and cells in late apoptosis or dead were both 
PE Annexin V-positive and 7-AAD-positive.
RNA extraction, reverse transcription and quantitative PCR. 
Total RNA was extracted from the cell pellets or tissues using 
TRIzol reagent (Invitrogen) according to the manufacturer's 
instructions. The reverse transcription reaction was performed 
using a high capacity cDNA reverse transcription kit (4375575; 
Applied Biosystems, Foster City, CA, USA). The cDNA was 
subjected to PCR in the presence of SYBR-Green dye, with 
the ABI power SYBR-Green PCR Master Mix kit (4367659; 
Applied Biosystems). Quantitative PCR was performed on a 
7500 real-time PCR instrument (Applied Biosystems). Mouse 
primers were designed using Primer 3 and were synthesized 
by SBS Genetech Co., Ltd. (Beijing, China) (Table I). The 
relative mRNA levels of genes were calculated using the 2-∆∆Ct 
formula, and mouse β-actin was used as a housekeeping gene. 
All experiments were performed independently 3 times, and 
the average was used for comparison.
Protein extraction and western blot analysis. The preparation 
of protein extracts from frozen livers or isolated cells, electro-
phoresis, and subsequent blotting were performed as previously 
described (22,23). We incubated the blots with primary 
antibodies to B cell lymphoma/leukemia (Bcl)-2 (1:1,000; 
50E3), Bcl-2-associated X protein (Bax, 1:1,000; 2772), 
cleaved caspase-3 (1:1,000; 5A1E) (all from Cell Signaling 
Technology), α-SMA (1:2,000; 5694), tissue inhibitor of metal-
loproteinases (TIMP)-1 (1:1,000; 38978) (both from Abcam) 
and β-actin (1:5,000; A1978; Sigma, St. Louis, MO, USA) at 
4˚C overnight. This was followed by the addition of the appro-
priate horseradish peroxidase-conjugated secondary antibody 
(1:10,000; ZB2301 or ZB2306; ZSGB Bio, Beijing, China) and 
incubation for 60 min and specific antibody-antigen complexes 
were detected with the ECL western blot detection kit (Pierce, 
Rockford, IL, USA). All experiments were performed indepen-
dently at least 3 times, and protein expression was quantified 
by densitometric analysis of immunoblots using Quantity One 
software (Thermo Fisher Scientific, Waltham, MA, USA).
Statistical analysis. Data are expressed as the means ± stan-
dard deviation (SD). Two-group comparisons were conducted 
using the Student's t-test, and comparisons of the means of 3 or 
more groups were performed by ANOVA. A value of P<0.05 
was considered to indicate a statistically significant difference.
Results
Effects of hSAP pre-treatment on the histopathological 
changes in the livers of mice. H&E staining of the liver tissue 
sections revealed severe and diffuse centrilobular necrosis in 
the mice at 24 h following CCl4 administration. By contrast, 
Table I. Primers used for quantitative PCR.
Gene Forward primer (5'→3') Reverse primer (5'→3')
IL-1β GGT CAA AGG TTT GGA AGC AG TGT GAA ATG CCA CCT TTT GA
IL-6 ACCAGAGGAAATTTTCAATAGGC TGATGCACTTGCAGAAAACA
TNF-α AGGGTCTGGGCCATAGAACT CCACCACGCTCTTCTGTCTAC
MCP-1 ATTGGGATCATCTTGCTGGT CCTGCTGTTCACAGTTGCC 
MIP-2 TCCAGGTCAGTTAGCCTTGC CGGTCAAAAAGTTTGCCTTG
CD11b GTTTGTTGAAGGCATTTCCC  ATTCGGTGATCCCTTGGATT
Bcl-2 CTT TCT GCT TTT TAT TTC ATG AGG CAG AAG ATC ATG CCG TCC TT
Bax GAT CAG CTC GGG CAC TTT AG TTG CTG ATG GCA ACT TCA AC
α-SMA GTTCAGTGGTGCCTCTGTCA ACTGGGACGACATGGAAAAG
TIMP-1 AGGTGGTCTCGTTGATTTCT GTAAGGCCTGTAGCTGTGCC
β-actin ATGGAGGGGAATACAGCCC TTCTTTGCAGCTCCTTCGTT
IL, interleukin; TNF-α, tumor necrosis factor-α; MCP-1, monocyte chemotactic protein-1; MIP-2, macrophage inflammatory protein-2; Bcl-2, B 
cell lymphoma/leukemia-2; Bax, Bcl-2 associated X protein; α-SMA, α-smooth muscle actin; TIMP-1, tissue inhibitor of metalloproteinases-1.
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only spotty necrosis of the hepatocytes was found in the 
livers of CCl4-challenged mice pre-treated with hSAP. In 
addition, less inflammatory cell infiltration was observed in 
the hSAP + CCl4 group compared with the CCl4 group and 
the vehicle + CCl4 group. Diffuse centrilobular necrosis and 
inflammatory reactions were decreased in each group 48 h 
after the CCl4 administration; however, hSAP administration 
continued to decrease the necrotic area and inflammatory reac-
tion at this time point (Fig. 1A and C).
hSAP pre-treatment inhibits CCl4-induced inflammatory cell 
infiltration and pro-inflammatory factors, and chemokine 
expression. CD45 cell surface antigen is a transmembrane 
protein expressed by all nucleated cells of hematopoietic origin, 
apart from erythrocytes and platelets (24). In this study, we 
used this marker to lable inflammatory cells in the injured 
liver. Immunohistochemical staining revealed that the number 
of CD45-positive cells accumulating in the liver sections was 
decreased by hSAP treatment compared with that of the CCl4 
Figure 1. Human serum amyloid P (hSAP) alleviates liver inflammatory reactions in mice with carbon tetrachloride (CCl4)-induced liver injury. Mice were 
treated intravenously with hSAP (12.5 mg/kg) or the vehicle for 2 h. The mice were then subcutaneously injected with 12.5% CCl4 for 24 or 48 h to develop an 
acute liver injury. (A) Liver sections from animal models were subjected to hematoxylin and eosin staining to detect histopathological changes (x200 magnifica-
tion). (B) Liver sections from animal models were subjected to immunohistochemical staining with CD45 for the detection of infiltrating inflammatory cells. 
(C) The percentage of necrotic area of 5 high-power fields at x200 magnification is shown. (D) The number of CD45-positive cells/total number of cells x100% 
of 5 high-power fields at x200 magnification is shown. Values are expressed as the means ± SD in each group. **P<0.01, n=8 mice/group. Scale bar, 50 µm.
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and vehicle + CCl4 groups (P<0.01; Fig. 1B and D). Exposure 
to CCl4 significantly increased the hepatic interleukin (IL)-1β, 
IL-6 and tumor necrosis factor (TNF)-α mRNA expression 
levels compared with those of the normal group, suggesting 
the induction of a severe inflammatory response. However, the 
pre-administration of hSAP suppressed the mRNA expression 
of hepatic IL-1β, IL-6 and TNF-α (Fig. 2A-C). In addition, 
the levels of chemokines that regulate inflammation, such 
as monocyte chemotactic protein (MCP)-1 and macrophage 
inflammatory protein (MIP)-2, were also detected. High expres-
sion levels of MCP-1 and MIP-2 were observed in the CCl4 and 
vehicle + CCl4 groups, whereas hSAP administration down-
regulated the expression of these chemokines (Fig. 2D and E). 
To confirm the inflammatory infiltration, we detected CD11b (a 
biomarker for neutrophils) expression in the liver. CD11b 
expression in the liver sections was decreased by hSAP treat-
ment compared with the injury group (Fig. 2F). The levels of all 
pro-inflammatory factors and chemokine expression in the 24-h 
group were higher than those in the 48-h group, indicating that 
acute liver injury induced by CCl4 reached a peak value at 24 h 
after CCl4 administration.
hSAP pre-treatment decreases CCl4-induced apoptosis in vivo. 
Previous studies have reported severe hepatocyte apoptosis in 
CCl4-induced acute liver injury (25,26). In this study, to clarify 
whether the effect of hSAP on acute liver injury was primarily 
due to its inhibitory effect on hepatocyte apoptosis, we 
performed TUNEL staining to assess the protective ability of 
hSAP against CCl4-induced hepatocyte apoptosis. The analysis 
of cleaved caspase-3 expression in the liver also revealed 
that the pre-administration of hSAP inhibited the increased 
apoptosis induced by exposure to CCl4 (Fig. 3A, B and D). 
To determine the mechanisms underlying the anti-apoptotic 
effects of hSAP, the expression of the apoptosis-related genes, 
Bcl-2 and Bax, in hepatocytes was detected using quantitative 
PCR and western blot analysis. The pre-administration of 
hSAP significantly upregulated the expression levels of Bcl-2 
and significantly downregulated the expression levels of Bax 
compared with those in the model group (Fig. 3C and D). The 
expression of Bcl-2, Bax and cleaved caspase-3 exhibited a 
significant difference in the hSAP pre-treatment group at 24 h 
following the CCl4 administration compared with the model 
group (P<0.05 or P<0.01).
hSAP pre-treatment decreases the CCl4-induced apoptosis of 
hepatocytes in vitro. To confirm the hepatocyte protective effects 
of hSAP, NCTC 1469 cells were cultured with hSAP (30 µg/ml) 
or the vehicle for 4 h prior to stimulation with CCl4 (2.5 mM). 
Four hours later, the cells were collected, and cell death was 
detected using an apoptosis detection kit. The number of cells 
in early apoptosis stained with Annexin V was significantly 
reduced by 28-30% in the hSAP treatment group compared with 
the CCl4 group (13.4±0.9 vs. 18.5±1.5%) (Fig. 4A). The expres-
sion of Bcl-2 was increased, whereas the expression levels of Bax 
and cleaved caspase-3 were significantly inhibited in the hSAP 
pre-treatment group compared with the CCl4 group (P<0.01), 
indicating that hSAP has a direct anti-apoptotic function on 
hepatocytes exposed to CCl4 (Fig. 4B-D).
Figure 2. Human serum amyloid P (hSAP) pre-treatment inhibits carbon tetrachloride (CCl4)-induced pro-inflammatory factors and chemokine expression 
in mouse livers. The mRNA expression of (A) interleukin (IL)-1β, (B) IL-6, (C) tumor necrosis factor (TNF)-α, (D) monocyte chemotactic protein (MCP)-1, 
(E) MIP-2 and (F) CD11b from a whole-liver sample was detected using quantitative PCR. β-actin was used as a loading control. *P<0.05 and **P<0.01, n=8 mice/
group. The results shown represent 3 independent experiments. 
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hSAP inhibits the migration and activation of HSCs in vivo. As 
activated HSCs secrete high levels of MCP-1 and MCP-1 in turn 
can promote the migration and positioning of HSCs (27,28), 
we further detected the migration of HSCs in injured livers. 
Although aggregated HSCs were found around the necrotic 
area at 24 and 48 h following the CCl4 administration, fewer 
HSCs migrated to these areas following hSAP administration, 
as confirmed by desmin staining (P<0.05; Fig. 5A and C). 
Figure 3. Human serum amyloid P (hSAP) pre-treatment inhibits carbon tetrachloride (CCl4)-induced apoptosis in vivo. (A) Liver sections were subjected to a 
terminal-deoxynucleotidyl transferase mediated nick-end labeling (TUNEL) assay to detect cell apoptosis (x400 magnification). Apoptotic hepatocytes were 
stained by green fluorescence. (B) The apoptotic index (number of positive cells/total number of cells x100%) of 5 high-power fields at x400 magnification is 
shown. (C) The mRNA expression of B cell lymphoma/leukemia-2 (Bcl-2) and Bcl-2 associated X protein (Bax) from a whole-liver sample was detected by real-
time PCR. β-actin was used as a loading control. (D) The protein level of Bcl-2, Bax and cleaved caspase-3 from a whole liver sample was detected by western 
blot analysis. *P<0.05 and **P<0.01, n=8 mice/group. The results shown represent 3 independent experiments.
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Subsequently, we used α-SMA, a biomarker of activated HSCs, 
to detect the activation of HSCs in the injured liver. Although 
there were a limited number of activated HSCs in each group 
at 24 h following the CCl4 administration, immunostaining 
Figure 4. Human serum amyloid P (hSAP) pre-treatment decreases the carbon tetrachloride (CCl4)-induced apoptosis of hepatocytes in vitro. NCTC 1469 cells 
were pre-treated with 30 µg/ml hSAP or the vehicle for 4 h and were then incubated with CCl4 (2.5 mM) for 4 h. (A) Cells were trypsinized and stained with 
Annexin V and 7-AAD followed by analysis with flow cytometry. Early apoptotic cells (Annexin V positive and 7-AAD negative) are in the right lower quadrant. 
Late apoptotic or necrotic cells are in the right upper quadrant. The ratio of early apoptotic cells to total cells x100% is shown. (B) The mRNA expression of 
B cell lymphoma/leukemia-2 (Bcl-2) and Bcl-2 associated X protein (Bax) from cells was detected using quantitative PCR. β-actin was used as a loading control. 
(C) The protein level of Bcl-2, Bax and cleaved caspase-3 from cells was detected by western blot analysis. (D) The expression levels of Bcl-2, Bax and cleaved 
caspase-3 were normalized to β-actin. **P<0.01. The results shown represent 3 independent experiments.
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of the tissue sections for α-SMA expression revealed intense 
staining patterns around the damaged hepatocytes in the mice 
from the CCl4 and the vehicle + CCl4 groups 48 h following 
the CCl4 administration. The administration of hSAP resulted 
in approximately 65% decreased positive staining in the sinu-
soids, demonstrating fewer activated HSCs following hSAP 
treatment (Fig. 5B and D).
hSAP inhibits the TGF-β1-induced activation of HSCs in vitro. 
CCl4 is a hepatotoxin, which causes the apoptosis of damaged 
hepatocytes. Apoptotic hepatocytes release factors that activate 
Kupffer cells, the major source of TGF-β1. Quiescent HSCs are 
induced by TGF-β1 to transdifferentiate into myofibroblasts 
that secrete extracellular matrix (2). Based on the observed 
weaker activation of HSCs in the injured liver of hSAP-treated 
Figure 5. Human serum amyloid P (hSAP) inhibits the infiltration and activation of hepatic stellate cells (HSCs) in vivo. (A) Liver sections from animal models 
were subjected to immunohistochemical staining with desmin for the detection of infiltrating HSCs, and the number of desmin positive cells/total number of 
cells x100% of 5 high-power fields at x200 magnification is shown (C). (B) Liver sections from animal models were subjected to immunohistochemical staining 
with α-smooth muscle actin (α-SMA) for the detection of activated HSCs, and the number of α-SMA positive cells/total number of cells x100% of 5 high-power 
fields at x200 magnification is shown (D). **P<0.01, n=8 mice/group. Scale bar, 50 µm.
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mice, we wished to elucidate whether hSAP inhibits the 
TGF-β1-induced activation of HSCs directly in vitro. Primary 
HSCs were isolated from wild-type C57BL/6 mice, and the 
purity was >98%, as assessed by desmin immunofluorescence 
staining and Oil Red O staining (Fig. 6A and B). Following 
24 h of incubation with TGF-β1, the isolated HSCs exhibited a 
significantly lower activation in the 30 µg/ml hSAP treatment 
group. The mRNA and protein levels of α-SMA and TIMP-1 in 
the hSAP treatment group were significantly reduced compared 
with those in the TGF-β1 group (Fig. 6C-E).
Discussion
Carbon tetrachloride is a widely used hepatotoxin to establish 
animal models for evaluating the hepatoprotective activities 
of drugs (29). In the present study, mice injected with CCl4 
exhibited characteristics of acute liver injury, including 
distorted hepatic parenchyma, inflammatory cell infiltra-
tion and hepatocyte necrosis (visualized by H&E staining). 
However, pre-treatment with hSAP significantly decreased the 
CCl4-induced histopathological changes in the livers. These 
Figure 6. Human serum amyloid P (hSAP) inhibits the transforming growth factor (TGF)-β1-induced activation of hepatic stellate cells (HSCs) in vitro. (A) The 
purity of isolated HSCs was assessed by immunoflurescence staining of desmin and Oil Red O staining (B). (C) Isolated primary HSCs were cultured with 
hSAP (30 µg/ml) or the vehicle for 4 h before stimulation with TGF-β1 (10 ng/ml for 24 h). The mRNA expression of α-smooth muscle actin (α-SMA) and tissue 
inhibitor of metalloproteinases (TIMP)-1 was detected by quantitative PCR. β-actin was used as a loading control. (D) The protein levels of α-SMA and TIMP-1 
were detected by western blot analysis. (E) The expression levels of α-SMA and TIMP-1 were normalized to β-actin. **P<0.01. The results shown represent 
3 independent experiments. Scale bar, 50 µm.
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findings indicate that hSAP can exert protective effects against 
CCl4-induced liver damage.
The inflammatory response is involved in the process of 
CCl4-induced acute liver injury (30). The traditional inflamma-
tory response is characterized as a complex reaction to an injuring 
agent that involves the loss of vascular wall integrity, the effusion 
of inflammatory cells, the activation of leukocytes and their 
extravasations, and the release of pro-inflammatory cytokines, 
such as TNF-α, IL-6 and IL-1β (31,32). In this study, the CD45 
antibody was used to stain inflammatory cells in liver sections, 
and we found that hSAP treatment significantly reduced inflam-
matory infiltration compared with the injury group. Exposure to 
CCl4 significantly upregulated the expression of pro-inflamma-
tory cytokines (TNF-α, IL-6 and IL-1β), chemokines (MCP-1 
and MIP-2) and CD11b (marker of neutrophil activation) in 
injured mouse livers. However, the pre-administration of hSAP 
markedly inhibited the upregulation of these pro-inflammatory 
cytokines, chemokines and leukocyte infiltration. These results 
suggested that hSAP can meliorate liver injury caused by CCl4 
by inhibiting the inflammatory response.
Previous studies have demonstrated that hepatocyte apop-
tosis can be triggered by CCl4 (25,26). In this study, the rate 
of apoptosis evaluated by TUNEL staining was significantly 
increased in the CCl4 group, which was decreased by the pre-
administration of hSAP. To investigate whether hSAP treatment 
modulates the molecular mechanisms involved in apoptosis, 
we detected the expression of apoptosis-related molecules, 
particularly Bcl-2 (anti-apoptotic protein), Bax (pro-apoptotic 
protein) and caspase-3. The present study demonstrated that 
the pre-administration of hSAP suppressed the upregulation 
of Bax expression, inhibited the activation of caspase-3, and 
restored Bcl-2 expression which was decreased by CCl4. The 
result that the mRNA expression of Bax reached a peak value at 
24 h following CCl4 administration, whereas Bax and cleaved-
caspase-3 protein bands in the western blots were far denser at 
48 h, could partially be explained by the timeline difference 
between the regulation of mRNA and protein expression. Our 
in vitro experiments also confirmed that hSAP significantly 
reduced the CCl4-induced early apoptotic rate in hepatocytes 
by regulating the expression of the apoptosis-related proteins, 
Bax and Bcl-2.
Several studies have proposed that the phagocytosis of 
apoptotic bodies by HSCs links cell death to HSC activation, 
showing increased HSC activation and survival after the 
phagocytosis of apoptotic bodies in vitro (33-35). DNA from 
apoptotic hepatocytes can provide a stop signal to mobile 
HSCs when they reach an area of apoptotic hepatocytes and 
induce a stationary phenotype-associated upregulation of 
collagen production (36). Apoptotic body engulfment in HSCs 
also stimulates TGF-β1 expression and induces collagen I, 
indicating a fibrogenic response (33). In this study, the immu-
nohistochemical staining of desmin (a biomarker for HSCs) 
and α-SMA (a biomarker for activated HSCs) showed that the 
pre-administration of hSAP inhibited the migration and activa-
tion of HSCs to the injured liver site and may be mediated by 
less apoptotic hepatocyte DNA in hSAP-pre-treated livers.
The short pentraxin, SAP, was recently described to reduce 
fibrosis in a number of different organ models, including 
pulmonary, renal, cardiac and oral submucous fibrosis, 
partially through the inhibition of fibrocyte and macrophage 
accumulation and activation in the injured organ (15,17,37-
40). It has been demonstrated that the anti-fibrotic effects of 
SAP in TGF-β1-induced lung fibrosis are mediated through 
the modulation of monocyte responses (17), and that SAP 
also inhibits fibrosis through Fcγ receptor (FcγR)-dependent 
monocyte-macrophage regulation (37). HSCs are the main 
cell type responsible for liver fibrosis, and TGF-β1 is the most 
potent cytokine that can promote the activation of HSCs (2). In 
this study, to determine whether hSAP inhibits the activation of 
HSCs directly, we isolated primary HSCs from normal mouse 
liver and incubated these primary HSCs with or without hSAP 
and with TGF-β1 stimulation. Although TGF-β1 activated 
HSCs by upregulating the expression of α-SMA and TIMP-1, 
the mRNA and protein levels of these profibrogenic genes in the 
hSAP treatment group were significantly reduced by 43-45% 
compared with the control group. It has been shown that hSAP 
serves as a ligand for activating FcγRs and downregulates the 
activation of monocytes and macrophages (37). Primary rat 
HSCs express FcγRs (41), suggesting that hSAP may also bind 
directly to HSCs via FcRs. Rat hepatocytes may express MHC 
class I-related Fc receptor for IgG (42). For our in vitro experi-
ment, we hypothesized that SAP could act on hepatocytes and 
HSCs by binding between SAP and FcγRs. Additional studies 
are required to fully investigate the mechanism through which 
hSAP inhibits the activation of HSCs.
In the present study, we demonstrated that hSAP has a 
strong anti-inflammatory and hepatoprotective effect in CCl4-
induced acute liver injury in mice, most likely through the 
combined effects of inhibiting leukocyte infiltration, inflam-
matory cytokine expression and hepatocyte apoptosis. hSAP 
may also inhibit HSCs activation directly or indirectly due to 
fewer apoptotic hepatocytes. Based on the intimate association 
between inflammation and fibrosis, the important role of HSCs 
in fibrogenesis and the inhibitory effects of hSAP on HSC acti-
vation, hSAP may also affect the development of liver fibrosis. 
Further studies are required to evaluate the role of SAP in liver 
fibrosis in vitro and in vivo.
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